BillionToOne IPO: Molecular diagnostics company debuts on the Nasdaq

Early trading in BillionToOne, a molecular diagnostics company that uses DNA to detect early signs of disease, has begun on the Freedom trading system. The IPO marks a milestone for one of the fastest-growing U.S. players in molecular diagnostics and comes amid a broader rebound in healthcare listings. Later today, November 6, the shares will start trading on the Nasdaq under the symbol BLLN.

BillionToOne raised $273.1 million in its IPO. The company sold 4.55 million shares at $60 per share, above the marketed range of $49-55 per share. The company’s market valuation thus stands at about $2.64 billion, Reuters writes.

The deal was arranged by JPMorgan, Piper Sandler, Jefferies, William Blair, Stifel, Wells Fargo Securities, and BTIG.

BillionToOne was founded in 2016 by Oguzhan Atay and David Tsao, who serve as CEO and CTO, respectively. The company develops technologies that analyze DNA at the single-molecule level, which enables earlier and more accurate detection of genetic and cancer-related conditions.

Its proprietary technology, Quantitative Counting Templates (QCT), allows the counting of individual DNA fragments in a blood sample to identify tiny genetic changes that conventional sequencing may miss. The company applies QCT in two main verticals: prenatal screening and oncology.

In 2019, BillionToOne launched UNITY, the first noninvasive prenatal test for fetal health screening using a single maternal blood draw. In 2023, it introduced two liquid-biopsy assays for broad cancer detection, meaning accurate tumor-cell quantification at the single-molecule level without tissue biopsies.

The company’s revenue more than doubled to $152.6 million in 2024, while its net loss narrowed to $41.6 million from $82.7 million in 2023. The improvement reflected scaling of operations and higher test volumes, Capital.com noted. In 2025, the management reported record demand and a robust reimbursement pipeline, reinforcing confidence in BillionToOne’s path toward profitability.

Freedom Finance analyst Alem Bektemirov has a target price of $70.40 per share for BillionToOne, implying upside of about 17% from the IPO price. However, the valuation remains sensitive to the revenue and margin outlook, he cautioned. A slowdown in testing volumes or margin pressure could weigh on the valuation, Bektemirov said.

Donovan Jones, an analyst at investment firm IPO Edge, noted that BillionToOne has showed rapid revenue growth, improving margins, shrinking operating losses, and positive operating cash flow. The IPO proceeds are to fund growth and R&D, but risks include strong competition, service-concentration exposure, and uncertainties around expansion and reimbursement, Jones wrote.

According to Capital.com, the offering reflects growing investor confidence in precision medicine and diagnostics companies – an approach that tailors prevention and treatment to an individual’s genetic and clinical profile. BillionToOne enters public markets after several years of expansion, joining a new wave of health-tech companies reshaping how genetic diseases are detected and monitored, the site writes.

The decision to go public underscores the company’s transition from early-stage innovation to established commercial revenue, which will make it more appealing to institutional investors focused on mature biotechs, Capital.com argues. The stock’s performance after listing will depend on the company’s scientific and clinical results, financial growth and operational discipline, competitive positioning, and investor sentiment toward the broader sector, it added.

BillionToOne competes with Natera, Guardant Health, Invitae, Myriad Genetics, and Exact Sciences. The global molecular diagnostics market is projected to reach $40-45 billion by 2030, with oncology and prenatal testing as the main growth drivers. Integrating both segments on a single platform could give BillionToOne a lasting competitive edge, Capital.com concluded.

__________________

Freedom clients will be able to get access to BillionToOne shares before the opening of the main exchange session. Trading will begin in the early pre-market format 2-3 hours before the opening of the US exchanges (from 15:30-16:30 Astana time). To participate, click on the ticker BLLN.

This article was AI-translated and verified by a human editor